Market Overview

Morgan Stanley Initiates Amneal Pharmaceuticals, Anticipates Outperformance

Share:
Morgan Stanley Initiates Amneal Pharmaceuticals, Anticipates Outperformance
Related
The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Amneal Pharmaceuticals (NYSE: AMRX) announced Monday the FDA approval of its newest drug, a generic version of Potassium Chloride oral solution.

The Analysts

Morgan Stanley analyst David Risinger initiated coverage with an Overweight rating for Amneal Pharmaceuticals, with a price target of $22.

The Thesis

Due to a strong execution of a new product and the history of this management team, Risinger expects a clear outperformance. He considers leadership a key catalyst for this endeavor.

“Executive Chairman Paul Bisaro and CEO Rob Stewart previously helped drive significant outperformance at Watson Pharma. Although historical performance is no guarantee of future results, we believe management has the right experience, track record,and team culture to deliver outperformance at Amneal,” Risinger said in a note.

With the anticipation of growth above competitors, Risinger notes the importance of quarterly performance, pipeline newsflow and external transactions.

Despite the question of performance in a challenging pricing environment, analysts remain optimistic for three reasons.

"(1) We expect US generics pricing pressure to moderate somewhat over the next year. (2) Amneal's diversified product portfolio helps support revenue prospects and durability. (3) The company's focus on limited competition/complex/high margin products and expectation of >$200M synergies should yield financial upside,” Risinger said.

Price Action

Amneal Pharmaceuticals shares were trading up 5 percent at $19.44 Monday morning.

Related Links:

Barclays: Impax Labs-Amneal Pharma Merger Creates A Generics Leader

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Latest Ratings for AMRX

DateFirmActionFromTo
Oct 2018SunTrust Robinson HumphreyDowngradesBuyHold
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Aug 2018B. Riley FBRMaintainsBuyBuy

View More Analyst Ratings for AMRX
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (AMRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ALRMImperial CapitalUpgrades58.0
ANDXSunTrust Robinson HumphreyDowngrades41.0
CMANomuraDowngrades86.0
CSLLongbow ResearchUpgrades122.0
HBANNomuraDowngrades15.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Alphabet Q2 Earnings Preview

Stifel Downgrades Papa John's To Sell Amid 'Fraternal Corporate Culture'